Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study
Objective: аssessment of orlistat, liraglutide and sibutramine consumption in the Russian Federation as drugs recommended by the Russian clinical guidelines for the pharmacotherapy of obesity.Material and methods. From IQVIA database, the information was selected on retail sales and procurement of t...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2022-10-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/707 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850031679392972800 |
|---|---|
| author | V. V. Strizheletsky Yu. М. Gomon Е. А. Spichakova А. S. Kolbin А. А. Kalyapin S. А. Makarov А. B. Lomiya F. М. Sultanova |
| author_facet | V. V. Strizheletsky Yu. М. Gomon Е. А. Spichakova А. S. Kolbin А. А. Kalyapin S. А. Makarov А. B. Lomiya F. М. Sultanova |
| author_sort | V. V. Strizheletsky |
| collection | DOAJ |
| description | Objective: аssessment of orlistat, liraglutide and sibutramine consumption in the Russian Federation as drugs recommended by the Russian clinical guidelines for the pharmacotherapy of obesity.Material and methods. From IQVIA database, the information was selected on retail sales and procurement of the specified drugs at the expense of the federal and regional budgets in the period of 2011–2021. The consumed volumes of each drug were recalculated into the number of defined daily doses (DDDs) for each international nonproprietary name in accordance with the World Health Organization methodology.Results. It was demonstrated that over a 10-year period there was a tendency to reduce the consumption of drugs for the treatment of obesity from 83.03 million DDDs in 2011 to 71.7 million in 2021. Sibutramine consumption dominated throughout the observation period: its share ranged from 76% to 84%. The proportion of people receiving obesity pharmacotherapy in the Russian Federation was about 0.5%. Herewith 58–66% of DDDs sales took place in 3 regions: Moscow, Moscow Region and Saint Petersburg.Conclusion. Low efficacy, high frequency of adverse effects, frequent weight gain after therapy termination, as well as low orientation of doctors to the need for pharmacotherapy are probably the main factors determining the low prevalence of using drugs for the treatment of obesity in Russia. |
| format | Article |
| id | doaj-art-6e6561d5d4da42cd83681100cb4238bb |
| institution | DOAJ |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2022-10-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-6e6561d5d4da42cd83681100cb4238bb2025-08-20T02:58:54ZrusIRBIS LLCФармакоэкономика2070-49092070-49332022-10-0115332033110.17749/2070-4909/farmakoekonomika.2022.149400Drug therapy for obesity in the Russian Federation: pharmacoepidemiological studyV. V. Strizheletsky0Yu. М. Gomon1Е. А. Spichakova2А. S. Kolbin3А. А. Kalyapin4S. А. Makarov5А. B. Lomiya6F. М. Sultanova7Saint Petersburg State University; Saint George City HospitalSaint George City Hospital; First Pavlov State Medical UniversitySaint George City HospitalSaint Petersburg State University; First Pavlov State Medical UniversityIQVIA Russia and CISSaint George City HospitalSaint George City HospitalSaint George City HospitalObjective: аssessment of orlistat, liraglutide and sibutramine consumption in the Russian Federation as drugs recommended by the Russian clinical guidelines for the pharmacotherapy of obesity.Material and methods. From IQVIA database, the information was selected on retail sales and procurement of the specified drugs at the expense of the federal and regional budgets in the period of 2011–2021. The consumed volumes of each drug were recalculated into the number of defined daily doses (DDDs) for each international nonproprietary name in accordance with the World Health Organization methodology.Results. It was demonstrated that over a 10-year period there was a tendency to reduce the consumption of drugs for the treatment of obesity from 83.03 million DDDs in 2011 to 71.7 million in 2021. Sibutramine consumption dominated throughout the observation period: its share ranged from 76% to 84%. The proportion of people receiving obesity pharmacotherapy in the Russian Federation was about 0.5%. Herewith 58–66% of DDDs sales took place in 3 regions: Moscow, Moscow Region and Saint Petersburg.Conclusion. Low efficacy, high frequency of adverse effects, frequent weight gain after therapy termination, as well as low orientation of doctors to the need for pharmacotherapy are probably the main factors determining the low prevalence of using drugs for the treatment of obesity in Russia.https://www.pharmacoeconomics.ru/jour/article/view/707obesitymorbid obesitypharmacotherapydrug treatmentpharmacoepidemiology |
| spellingShingle | V. V. Strizheletsky Yu. М. Gomon Е. А. Spichakova А. S. Kolbin А. А. Kalyapin S. А. Makarov А. B. Lomiya F. М. Sultanova Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study Фармакоэкономика obesity morbid obesity pharmacotherapy drug treatment pharmacoepidemiology |
| title | Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study |
| title_full | Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study |
| title_fullStr | Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study |
| title_full_unstemmed | Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study |
| title_short | Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study |
| title_sort | drug therapy for obesity in the russian federation pharmacoepidemiological study |
| topic | obesity morbid obesity pharmacotherapy drug treatment pharmacoepidemiology |
| url | https://www.pharmacoeconomics.ru/jour/article/view/707 |
| work_keys_str_mv | AT vvstrizheletsky drugtherapyforobesityintherussianfederationpharmacoepidemiologicalstudy AT yumgomon drugtherapyforobesityintherussianfederationpharmacoepidemiologicalstudy AT easpichakova drugtherapyforobesityintherussianfederationpharmacoepidemiologicalstudy AT askolbin drugtherapyforobesityintherussianfederationpharmacoepidemiologicalstudy AT aakalyapin drugtherapyforobesityintherussianfederationpharmacoepidemiologicalstudy AT samakarov drugtherapyforobesityintherussianfederationpharmacoepidemiologicalstudy AT ablomiya drugtherapyforobesityintherussianfederationpharmacoepidemiologicalstudy AT fmsultanova drugtherapyforobesityintherussianfederationpharmacoepidemiologicalstudy |